LGND Stock: Ligand Pharmaceuticals Incorporated Stock Price, Analysis & Insights
Get live LGND stock price $246.74, comprehensive Ligand Pharmaceuticals Incorporated stock analysis, charts, news, and expert forecast. Real-time LGND stock data and investment insights.
Loading chart data...
Ligand Pharmaceuticals Incorporated (LGND) Overview
Ligand Pharmaceuticals Incorporated (LGND) is a publicly traded company in the Healthcare sector , specifically within the Biotechnology industry . As of the latest trading session, LGND trades at $246.74 with a market capitalization of 4.94B . Over the past 52 weeks, LGND has traded between $110.00 and $257.19 , with the current price positioned at approximately 93% of this range . The stock c...
Key Takeaways
- Operates in the Healthcare sector (Biotechnology)
- Market cap: 4.94B
- Current price: $246.74
- 52-week range: $110.00 - $257.19
- P/E ratio: 32.13
Investment Score
A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. It...
Company Information
- CEO
- Todd C. Davis
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 68
Contact Information
- Website
- https://www.ligand.com
- Address
- 5980 Horton Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 32.1)
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Ligand Pharmaceuticals Incorporated shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Ligand Pharmaceuticals Incorporated
- ⚠Investors should consider how Ligand Pharmaceuticals Incorporated fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 32.1) requires strong growth to justify
Market Cap
4.94B
P/E Ratio (TTM)
32.13
Beta
1.04
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare LGND with peer companies:
- Price
- $21.49
- Market cap
- 3.68B
- Price
- $8.57
- Market cap
- 1.99B
- Price
- $139.63
- Market cap
- 5.60B
- Price
- $35.10
- Market cap
- 3.70B
- Price
- $17.84
- Market cap
- 2.95B
- Price
- $95.33
- Market cap
- 4.79B
- Price
- $29.72
- Market cap
- 3.47B
- Price
- $243.10
- Market cap
- 5.14B
- Price
- $53.01
- Market cap
- 2.76B
- Price
- $27.96
- Market cap
- 3.25B
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.